文献速递血栓与止血

接受利妥昔单抗治疗免疫性血小板减少症的成年患者循环血淋巴细胞评估:循环NK细胞数量与6个月时的应答相关

Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months.
PubMed 文献 · Br J Haematol · 2023-04-20

该回顾性研究分析了2007至2021年间接受利妥昔单抗治疗持续性/慢性免疫性血小板减少症(ITP)的72例患者,按6个月时血小板计数分为完全应答、部分应答和无应答三组。研究发现,低数量的CD3- CD16+ CD56+循环NK细胞与利妥昔单抗完全应答相关;利妥昔单抗治疗后,完全应答者NK细胞百分比升高而活化CD8+ T细胞百分比降低。

要点

  • 低数量的CD3- CD16+ CD56+循环NK细胞与利妥昔单抗治疗ITP的完全应答相关。
  • 利妥昔单抗治疗后,完全应答者NK细胞百分比升高、活化CD8+ T细胞百分比降低。
  • 血液淋巴细胞亚群数据可方便地用于推导利妥昔单抗应答的预测因素。

核心结论

  • 低数量的CD3- CD16+ CD56+循环NK细胞与利妥昔单抗治疗持续性/慢性ITP的完全应答相关。
  • 利妥昔单抗治疗后,完全应答者表现出NK细胞百分比升高和活化CD8+ T细胞百分比降低。
  • NK细胞在ITP中的作用仍不完全清楚,但血液淋巴细胞亚群数据可方便地用于推导利妥昔单抗应答的预测因素。

研究设计与样本

  • 回顾性分析2007至2021年间在本科室随访的72例接受利妥昔单抗治疗持续性/慢性ITP的成年患者的临床病程、生物学标志物和血淋巴细胞亚群数量。
  • 按6个月时血小板计数将患者分为完全应答、部分应答和无应答三组。

主要发现

  • 在所有研究的参数中,低数量的CD3- CD16+ CD56+循环NK细胞与利妥昔单抗的完全应答相关。
  • 利妥昔单抗治疗后,完全应答者NK细胞百分比升高而活化CD8+ T细胞百分比降低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is defined by a low platelet count that can trigger potentially life-threatening haemorrhages. Three-quarters of adult patients exhibit persistent or chronic disease and require second-line treatments. Among these, rituximab, an anti-CD20 antibody, has yielded valuable results, with global responses in 60% of patients at 6 months and complete responses in 30% at 5 years. Factors predictive of response to ITP therapy would help physicians choose optimal treatments. We retrospectively analysed clinical courses, biological markers and blood lymphocyte subset numbers of 72 patients on rituximab to treat persistent/chronic ITP followed-up in our department between 2007 and 2021, divided into three groups according to the platelet count at 6 months: complete, partial or no response. Among all studied parameters, a low number of CD3- CD16+ CD56+ circulating NK cells was associated with the complete response to rituximab. We also found that, after rituximab therapy, complete responders exhibited increased NK and decreased activated CD8+ T cell percentages. These results emphasize that the role played by NK cells in ITP remains incompletely known but that factors predictive of response to rituximab can be easily derived using blood lymphocyte subset data.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rivière E, Thiébaut R, Lazaro E, et al. Assessment of circulating blood lymphocytes in adult patients on rituximab to treat immune thrombocytopenia: Circulating number of NK cells is associated with the response at 6 months. Br J Haematol. 2023. PMID: 37081607. doi:10.1111/bjh.18818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。